Canopy's sales grow but US hopes stall and dilution forces reverse split
Sales growth and shrinking losses Canopy's quarterly revenue rose 13% to C$81.2 million, gross margin improved to 31%, and its adjusted EBITDA loss shrank 59%. Management still targets positive EBITDA this fiscal year. In plain terms, the business is losing less money and selling more, which supports the stock's value.
Shows the fundamental improvement that is the main positive force on CGC.
Debt cut, net cash, medical cannabis growth Canopy finished a major recapitalization that slashed debt and left it with about $131.3 million in net cash. Canadian medical cannabis revenue grew 27% and international medical grew 68%, led by Germany. Less debt and more cash make the company financially safer.
Highlights the balance-sheet repair and medical growth that reduce risk for CGC.
UK medical market entry Canopy signed a supply deal to sell four Canadian-grown medical cannabis strains in the United Kingdom through distributor GROW Group, under its Spectrum Therapeutics brand. This opens a new market for its products, which can add future revenue and supports the stock.
A concrete new distribution deal that expands demand for CGC's products.
US rescheduling stalls and heavy dilution US medical marijuana was rescheduled to Schedule III in April 2026, but broader recreational reforms that would help Canopy USA were left out, so the expected US boost has not materialized. Meanwhile, share count ballooned from 240 million to 423 million, and another $200 million ATM program could dilute holders further. More shares means each existing share is worth less.
Explains the two main forces keeping CGC's stock under $1 despite better sales.
Another reverse stock split to protect listing With shares back below $1, Canopy is asking shareholders on Sept. 25 to approve another reverse stock split, after a 2023 split was followed by an 80% drop. A reverse split is a sign the company has no better option and often signals underlying weakness, weighing on sentiment.
A new negative event that directly reflects the stock's listing pressure.